Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
Anti-RBD IgG concentration Geometric Mean Fold Rise from Day0 (pre-vaccination) to Day42 (post second-dose) for all formulation C&B cohorts from Phase-1/2 and Formulation-E cohort from Phase II study.
| Formulation | Day42 GMFR | % Seroconversion at Day42 |
|---|---|---|
| C | 22·03 | 82% |
| B | 25·15 | 88% |
| E | 27·99 | 89% |
GMFR: Geometric mean fold rise; IgG: Immunoglobulin G.
Note: Percentage seroconversion observed for Day42 time-point sera samples based on ≥4-fold rise in anti-RBD-IgG concentration is also reported.
